UNCLAIMED
Ceribell
Overview
Ceribell, founded in 2014 and based in the United States, operates within the manufacturing sector, specifically focusing on medical devices and equipment. The company has established itself in the field of point-of-care (POC) electroencephalography (EEG), addressing the critical need for timely EEG access in clinical settings. Ceribell's technology is recognized for its rapid configuration capabilities, allowing for setup times significantly shorter than traditional methods, which enhances clinical efficiency in urgent situations. The company’s POC EEG system is positioned as a complementary tool in neuromonitoring, aiding clinicians in making swift decisions regarding patient care. Insights from a recent technical report highlight the integration of artificial intelligence and machine learning in EEG interpretation, which may further improve bedside care. The company’s commitment to safety is underscored by the use of disposable, wet electrodes that provide reliable signals while minimizing infection risks. Ceribell’s innovations aim to streamline workflows and enhance patient outcomes in critical care environments, as evidenced by their contributions to clinical literature.